Johnson and Johnson Share Price – Live Data and Key Metrics
Johnson & Johnson (NYSE: JNJ) trades at approximately $244 to $245 per share as of early April 2026, reflecting a period of significant appreciation from its 52-week lows. The pharmaceutical giant’s stock has demonstrated resilience amid market volatility, with shares hovering near all-time highs established in March 2026.
The New Brunswick-based company maintains a market capitalization ranging between $450 billion and $590 billion, depending on calculation methods and timing of data updates. Investors monitoring real-time NYSE quotes observe fluctuations within a narrow band, with intraday movements typically contained within a $3 range.
Current metrics position JNJ as a low-volatility defensive holding with a beta of 0.17 and an indicated dividend yield between 2.13% and 2.73%.
What is the Current Johnson & Johnson (JNJ) Share Price?
- Shares reached an intraday high of $247.20 on April 1, 2026, with a low of $244.06 during the same session, according to Robinhood trading data.
- The stock exhibits low volatility with a beta of 0.17, significantly below the market average of 1.0.
- Average daily trading volume stands at 8.19 million shares, indicating substantial liquidity.
- Price discrepancies between data providers reflect timing differences in quote updates rather than arbitrage opportunities.
- The indicated annual dividend yield positions JNJ as a moderate income play within the healthcare sector.
- Current valuations place the price-to-earnings ratio between 18.37 and 22.15.
| Metric | Value | Source |
|---|---|---|
| Last Price (NYSE) | $244.12 | TradingView |
| 24h Change | -0.16% | TradingView |
| Market Cap | $590.70B | Robinhood |
| P/E Ratio (TTM) | 18.37 – 22.15 | TradingView / Robinhood |
| EPS (TTM) | $10.44 | TradingView |
| Dividend Yield | 2.13% – 2.73% | TradingView / Robinhood |
| 52-Week High | $251.71 | Robinhood |
| 52-Week Low | $141.50 | Robinhood |
| Beta (1Y) | 0.17 | TradingView |
| Shares Float | 2.41B | TradingView |
How Has JNJ Stock Performed Recently?
Year-to-Date and Annual Returns
Trading Economics data indicates a 59.12% annual increase, while alternative calculations show a 16.01% gain over the last 12 months and 35.31% year-to-date as of October 2025. These variations stem from different base dates and calculation methodologies.
The stock achieved its all-time high of $251.27 on March 5, 2026, surpassing previous records set in October 2025. This milestone represented a dramatic recovery from the 52-week low of $141.50, marking an approximate 77% gain from trough to peak.
Short-Term Volatility
Recent trading sessions have shown mixed signals. The stock declined 1.77% over a 24-hour period, yet posted a 0.51% gain on March 31, 2026. Weekly performance shows a 1.65% decline despite a 0.37% increase in market capitalization, suggesting share count adjustments or float changes.
With a beta coefficient of 0.17, JNJ exhibits approximately one-sixth the volatility of the broader S&P 500 index. This low-beta characteristic makes the stock particularly attractive for risk-averse portfolios seeking pharmaceutical exposure without significant market correlation.
What Are Key Financial Metrics for JNJ?
Market Capitalization and Valuation
The company’s market valuation fluctuates between $450.37 billion and $590.70 billion depending on the data provider and timing of calculations. This disparity highlights the importance of verifying timestamp data when assessing real-time enterprise value. Revenue for the fiscal year stands at $88.82 billion, generating net income of $14.07 billion according to exchange filings.
Earnings and Dividend Metrics
Basic earnings per share for the trailing twelve months reached $10.44, supporting the current P/E ratio range of 18.37 to 22.15. The dividend yield, calculated on an indicated annual basis, ranges from 2.13% to 2.73%, positioning JNJ as a moderate income play within the healthcare sector.
Johnson & Johnson’s $88.82 billion annual revenue places it among the largest pharmaceutical companies globally. The net income margin of approximately 15.8% reflects operational efficiency typical of established pharma giants with diversified product portfolios.
What Do Analysts Say About JNJ Stock Outlook?
Price Targets and Consensus
Analysts maintain divergent views on JNJ’s trajectory. TradingView aggregates indicate a maximum price target of $240 and minimum of $176, suggesting potential downside risk from current levels. Conversely, TradingEconomics forecasts a Q1 2026 target of $233.24 and a one-year projection of $212.87, implying anticipated volatility.
The consensus characterization remains “undervalued with strong fundamentals,” though this assessment predates the stock’s ascent to $245 levels. Technical analysis from Investing.com notes steady performance characteristics typical of defensive pharmaceutical holdings.
Current trading prices exceed some analyst maximum targets, creating a discrepancy between market pricing and professional forecasts. This gap suggests either underestimated growth potential or elevated valuation risk not fully reflected in historical models.
What Recent Events Impact JNJ Share Price?
- : Stock reaches all-time high of $251.27, establishing new resistance levels.
- : Four-week low of $237.02 recorded, representing a 1.14% decline over the monthly period.
- : FY2025Q4 earnings report released with actual EPS of $2.04 versus consensus estimate of $2.53, marking a significant miss.
- : FY2025Q3 earnings show $2.75 actual versus $2.80 consensus, a narrow miss of five cents per share.
- (Scheduled): FY2026Q1 earnings release with consensus estimate of $2.69, down from previous $2.77.
What Information Is Definitive Versus Uncertain?
Established Data
- Current share price: $244-245 range verified across multiple exchanges
- 52-week high: $251.71 (Robinhood) / $251.27 (TradingEconomics)
- FY revenue: $88.82 billion
- Next earnings date: April 14, 2026
- Beta coefficient: 0.17 (low volatility confirmed)
Uncertain or Disputed
- Exact market cap: Variations between $450B and $590B reflect float calculation differences
- YTD performance: Ranges from 16.01% to 59.12% depending on measurement period
- Analyst accuracy: Current price exceeds some maximum targets
- Premarket pricing: Limited verified data available in research
- Competitor comparisons: No specific peer analysis data verified
How Does JNJ Fit Into Broader Market Context?
Johnson & Johnson operates as a bellwether pharmaceutical stock, often referenced alongside other defensive healthcare positions. The company’s Morningstar listing reflects its status as a large-cap staple with consistent dividend history spanning decades.
The stock’s low beta of 0.17 indicates minimal correlation with broader market indices, making it a traditional safe-haven holding during periods of economic uncertainty. This characteristic aligns with investor behavior observed during recent market fluctuations, where JNJ maintained relative stability compared to technology and cyclical sectors.
Investors seeking comparable retail investment analysis might reference the B and Q Kitchens – 2025 Prices and Quality Guide for insights into consumer discretionary sectors, though pharmaceutical valuations follow fundamentally different metrics than home improvement retail.
What Do Verified Sources Confirm?
Primary sourcing for JNJ financial data remains the company’s official investor relations portal, which provides definitive records for stock splits, dividend history, and SEC filings. The SEC EDGAR database hosts quarterly and annual reports under CIK 200406.
Data inconsistencies arise from different update times; prioritize recent NYSE quotes for accuracy.
TradingView and Robinhood methodology notes
Exchange-traded price verification through NYSE official channels provides the most reliable real-time data, while aggregated platforms like Yahoo Finance offer supplementary charting tools.
What Is the Bottom Line for JNJ Investors?
Johnson & Johnson trades near historical highs at approximately $245 per share, supported by a $450+ billion market capitalization and defensive low-beta characteristics. While analyst targets lag current prices, the company’s $10.44 TTM earnings and stable dividend yield of 2.1-2.7% sustain institutional interest. Investors monitoring seasonal patterns should note the upcoming April 14, 2026 earnings release as the next significant volatility catalyst. For those tracking international market schedules, the UK Time Change 2025 – When Clocks Spring Forward and Fall Back provides relevant context for global trading hours coordination.
Frequently Asked Questions
What is JNJ’s historical share price chart showing?
The stock has climbed from a 52-week low of $141.50 to current levels near $245, representing a 77% gain. The all-time high of $251.27 was reached on March 5, 2026.
Does Johnson & Johnson have a stock split history?
Yes. Detailed split history is available through the official JNJ investor relations site, including historical adjustments and dividend records dating back multiple decades.
How does JNJ compare to pharmaceutical competitors?
Specific competitor comparison data was not available in verified research. JNJ’s $88.82B revenue and 0.17 beta distinguish it as a large-cap defensive play, though direct peer analysis requires additional SEC filing review.
What is JNJ’s premarket share price?
Premarket pricing data varies by broker and was not consistently reported across verified sources. Real-time quotes typically become reliable at market open (9:30 AM ET).
Is JNJ stock considered a good buy currently?
Analyst consensus previously characterized JNJ as undervalued, though current prices exceed some maximum targets. The 2.13-2.73% dividend yield and low volatility appeal to income-focused investors.
When did JNJ last report earnings?
The company reported FY2025Q4 results on January 21, 2026, with EPS of $2.04 missing the $2.53 consensus estimate.
What is the significance of JNJ’s 0.17 beta?
The beta indicates the stock moves only 17% as much as the overall market, providing significant downside protection during broad market declines but limiting upside participation during rallies.
More related posts
LG 65 Inch TV: Best Prices & Reviews in Ireland
What Is a ZIP Code? Definition and Differences from Postcodes
Ash Blonde Hair Color: Shade, Suitability & Care
British Airways Baggage Allowance: 2026 Rules & Fees
King Size Bed in cm: Ireland 150 x 200 cm Standard
Darling Buds of May – Cast, Book, Remake Guide
Corus Hotel Hyde Park Closure, Rebranding & What’s Next
Winter Fuel Allowance Scrapped – 2025 Eligibility Guide
